Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La levofloxacine (Tavanic).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(11), 1015-7

Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the fluoroquinolone ... [more ▼]

Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the fluoroquinolone family and exerts a bactericidal activity upon a large spectrum of microorganisms, including Gram negative and Gram positive bacilli (among which Streptococcus pneunomiae), and atypical respiratory pathogens. It also has interesting pharmacokinetic properties. Besides the classical indications of other fluoroquinolones (especially complicated urinary tract infections, including pyelonephritis, and severe skin and soft tissue infections), levofloxacin is indicated for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia. [less ▲]

Detailed reference viewed: 79 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La moxonidine (Moxon).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(1), 61-3

Moxonidine (Moxon, Solvay Pharma) is the first member of a new class of centrally-acting antihypertensive agents. The selective activation of central I1 imidazoline receptors results in an inhibition of ... [more ▼]

Moxonidine (Moxon, Solvay Pharma) is the first member of a new class of centrally-acting antihypertensive agents. The selective activation of central I1 imidazoline receptors results in an inhibition of peripheral sympathetic activity and produces arterial vasodilatation. Moxonidine is indicated in the treatment of essential arterial hypertension, at a usual daily dose of 0.4 mg (initial dose of 0.2 mg/day), in one administration per day. Its tolerance profile is better than that of other centrally-acting antihypertensive agents which stimulate alpha-2 adrenergic receptors, and similar to that of medications of other classes. As monotherapy, the antihypertensive efficacy of moxonidine is similar to that of most other antihypertensive agents. In case of insufficient response, moxonidine may be associated with other antihypertensive compounds, which leads to a better efficacy with no deterioration of its good tolerance profile. [less ▲]

Detailed reference viewed: 167 (1 ULg)
Peer Reviewed
See detailPharma-Clinics. Le medicament du mois. La ranitidine bismuth citrate (Pylorid).
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(1), 41-4

Ranitidine bismuth citrate (Pylorid, Glaxo-Wellcome) is a novel salt of ranitidine which provides a unique combination of properties: inhibition of secretion of gastric acid by competitive antagonism of ... [more ▼]

Ranitidine bismuth citrate (Pylorid, Glaxo-Wellcome) is a novel salt of ranitidine which provides a unique combination of properties: inhibition of secretion of gastric acid by competitive antagonism of the action of histamine at the histamine H2-receptor on the gastric parietal cell, mucosal protective effects and anti-Helicobacter pylori action. Ranitidine bismuth citrate provides effective healing and symptom relief, both in duodenal ulcer disease and in gastric ulcer disease. When coprescribed with certain antibiotics (clarithromycin alone or combined with amoxicillin or nitro-imidazole), it heals ulcers, eradicates Helicobacter pylori and prevents recurrence of the disease. Several clinical studies demonstrated that ranitidine bismuth citrate is well-tolerated and has quite similar efficacy as proton pump inhibitors. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La sibutramine (Reductil).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(9), 656-9

Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity. It is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which exerts its ... [more ▼]

Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity. It is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which exerts its effects in vivo predominantly via its secondary and primary amine metabolites. Sibutramine is indicated as an adjunctive therapy within a weight management programme in patients with obesity (BMI > or = 30 kg/m2) or in overweight subjects (BMI > or = 27 kg/m2) if other eight-related risk factors are present (dyslipidaemias, diabetes mellitus). In those patients with an inadequate response on initial dose of 10 mg per day (suggested as less than 2 kg weight loss in four weeks), the dose may be increased to 15 mg once daily, providing that sibutramine is well tolerated. Several large-scale randomized clinical trials demonstrated the efficacy of long-term (at least one year) treatment with sibutramine in obese subjects with or without type 2 diabetes. Sibutramine was also shown to help in maintaining long-term weight reduction. Most frequent side-effects are dry mouth and constipation, as well as mild increase in heart rate and arterial blood pressure. The impact of sibutramine on cardiovascular morbidity and mortality of obese nondiabetic and diabetic patients will be studied soon in a large international prospective clinical trial. [less ▲]

Detailed reference viewed: 76 (2 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le celecoxib (Celebrex).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(1), 53-5

Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Its current indications are ... [more ▼]

Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Its current indications are osteoarthritis and rheumatoid arthritis. The usual recommended daily dosage of celecoxib is 200 mg (in one or two intakes per day), to be increased up to 400 mg (two intakes per day) if necessary. Its clinical efficacy seems to be similar to that of other NSAIDs. However, its safety profile, especially gastro-intestinal tolerance and perhaps renal safety, is much better because of the COX-2 selectivity. [less ▲]

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le formoterol (Oxis Turbohaler).
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(11), 715-8

Formoterol, commercialized by Astra under the trade name Oxis, is a new potent and selective agonist of beta-2 adrenergic receptors, which is used with a specific device (Turbohaler) allowing effective ... [more ▼]

Formoterol, commercialized by Astra under the trade name Oxis, is a new potent and selective agonist of beta-2 adrenergic receptors, which is used with a specific device (Turbohaler) allowing effective inhalation. Bronchodilatation occurs rapidly, within 1-3 minutes after inhalation, and lasts about 12 hours after the administration of a unique dose. Oxis Turbohaler is indicated to reduce symptoms associated with bronchial obstruction in asthmatic patients when the control of asthma is not achieved with inhaled corticoid therapy. It is not indicated for the treatment of acute crisis. It is presented as powder vials for inhalation (4.5 or 9 micrograms per dose). The usual dose in adults is 1-2 inhalations 1-2 times per day, in the morning and/or in the evening (bedtime administration should be recommended in case of nocturnal asthma). There is not enough data for treating children. The lowest dose allowing adequate control of asthma should be selected for chronic treatment. [less ▲]

Detailed reference viewed: 36 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le glimepiride (Amarylle).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(3), 184-6

Glimepiride, commercialized in Belgium under the trade name of Amarylle by Aventis, is a new sulphonylurea compound which is indicated in the treatment of type 2 diabetes, after diet and exercise failure ... [more ▼]

Glimepiride, commercialized in Belgium under the trade name of Amarylle by Aventis, is a new sulphonylurea compound which is indicated in the treatment of type 2 diabetes, after diet and exercise failure. It is available as 2 mg tablets. The initial doses is 1 mg, to be progressively increased up to 4 mg per day, if necessary, with a maximal daily dose of 6 mg. It is recommended to take glimepiride once a day, with the first main meal. Because of a particular binding of this sulphonylurea to the B cells of Langerhans pancreatic islets and, perhaps, of the presence of some extrapancreatic effects, both hypoglycaemic risk and circulating plasma insulin levels are lower with glimepiride than with glibenclamide, the reference sulphonylurea agent used in comparative clinical trials. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le Legalon (silymarine).
Luyckx, Françoise ULg; Scheen, André ULg

in Revue Médicale de Liège (1997), 52(12), 792-6

Detailed reference viewed: 173 (1 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le repaglinide (NovoNorm).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(6), 456-9

Repaglinide (NovoNorm) is an antidiabetic oral agent of the new glinide class with insulinotropic activity. Its action on insulin secretion is more rapid and shorter than that of sulphonylurea compounds ... [more ▼]

Repaglinide (NovoNorm) is an antidiabetic oral agent of the new glinide class with insulinotropic activity. Its action on insulin secretion is more rapid and shorter than that of sulphonylurea compounds. Thanks to these properties, repaglinide is able to better control postprandial hyperglycaemia and is associated with a lower risk of delayed hypoglycaemic episodes. It is indicated for the treatment of type 2 (non-insulin-dependent) diabetes mellitus as monotherapy, after diet failure, or in combination with metformin, when the biguanide is insufficient. NovoNorm is commercialized as tablets of 0.5, 1 and 2 mg, to be taken just before each meal. Initial dosis should be 0.5 mg before meal in diabetic patients on diet alone or 1 mg before meal in patients already receiving an hypoglycaemic agent. If necessary, the dosis should be progressively increased, depending on the individual response, up to 4 mg before meal (maximal daily dosage of 16 mg), in order to optimize blood glucose control. [less ▲]

Detailed reference viewed: 51 (2 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le rofecoxib (Vioxx).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(7), 751-3

Rofecoxib (Vioxx, Merck Sharp & Dohme) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as a nonsteroidal anti-inflammatory drug (NSAID). It is indicated in the ... [more ▼]

Rofecoxib (Vioxx, Merck Sharp & Dohme) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as a nonsteroidal anti-inflammatory drug (NSAID). It is indicated in the symptomatic relief of pain due to osteoarthritis. The initial oral dosage of rofecoxib is 12.5 mg once daily in adults, and this dose may be increased up to a maximal dosage of 25 mg once daily if necessary. Its clinical efficacy seems to be similar to that of other NSAIDs at maximal recommended dosages, but its safety profile, especially gastrointestinal tolerance, is much better because of the COX-2 selectivity. Ongoing clinical trials are performed in patients with rheumatoid arthritis. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Premelle (oestrogenes conjugues + medroxyprogesterone).
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(10), 638-40

Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems ... [more ▼]

Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems, among which vasomotor symptoms, atrophic vaginitis and/or urethritis, and in the prevention and treatment of post-menopausal osteoporosis. It is presented in two formulations, Premelle cyclic 5 and Premelle 5. The former, in which the progestagen is only given during the last 14 out of 28 days of the treatment cycle, is accompanied by regular bleeding and thus preferably indicated during perimenopause whereas the latter, in which the progestagen is given continuously and results in amenorrhea, is mostly indicated after menopause in order to improve long-term compliance. [less ▲]

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailPharmaceutical and nutraceutical management of canine osteoarthritis: Present and future perspectives
Henrotin, Yves ULg; Sanchez, Christelle ULg; Balligand, Marc ULg

in Veterinary Journal (2005), 170(1), 113-123

Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases and causes of lameness in the dogs. The osteoarthritic disease process involves the entire synovial joint, encompassing the ... [more ▼]

Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases and causes of lameness in the dogs. The osteoarthritic disease process involves the entire synovial joint, encompassing the synovium, cartilage and underlying bone. Joint failure results from an abnormal mechanical strain causing damage to normal tissue or failure of pathologically impaired articular cartilage and bone under the influence of normal physiological strain or a combination of both. In both cases, the end point is cartilage loss and joint impairment. Osteoarthritic chondrocytes show an altered phenotype characterised by an excess production of catabolic factors, including metalloproteinases and reactive oxygen species. These factors constitute potential therapeutic targets and some new drugs and nutraceuticals have been proposed to promote the return to homeostasis. Until now, the therapeutic management of OA in dogs has been dominated by nonsteroidal anti-inflammatory drugs, but some new compounds, including diacerhein, with potential structure-modifying effects, are already used to treat OA in humans and could be helpful to manage OA in the dog. In addition, novel nutraceuticals, such as avocado/soybean unsaponifiable substances, have shown symptomatic effects in knee OA in humans, and could offer an alternative to prevent OA progression. This paper provides an overview of recent discoveries in the pathophysiology and in the therapeutic management of osteoarthritis in dogs. (c) 2004 Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 75 (13 ULg)
Full Text
See detailLa pharmacie et ses usagers : perspectives éthiques
Caeymaex, Florence ULg

in Tous dopés? Ethique de la médecine d'amélioration (2009)

Detailed reference viewed: 14 (1 ULg)
Full Text
See detailLE PHARMACIEN HOSPITALIER : SITUATION EN 2008 ET PERSPECTIVES
Van Hees, Thierry ULg

Conference given outside the academic context (2008)

Detailed reference viewed: 25 (9 ULg)
Peer Reviewed
See detailPharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant le rapport cout/efficacite.
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(5), 270-5

The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot ... [more ▼]

The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot of factors may influence the cost-effectiveness ratio of the pharmacological intervention, especially the mode of calculation of various costs, the initial level of cardiovascular risk of the patients and the medico-economical particularities of each country. What so ever, available studies appear to justify the use of statins in secondary prevention, i.e. in coronary patients, even those with only a moderate hypercholesterolaemia, and, in primary prevention, i.e in hypercholesterolaemia individuals with obvious high risk of cardiovascular disease. [less ▲]

Detailed reference viewed: 36 (5 ULg)